PDB24 DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY TO METFORMIN (MET)
May 1, 2011, 00:00
10.1016/j.jval.2011.02.532
https://www.valueinhealthjournal.com/article/S1098-3015(11)00671-1/fulltext
Title :
PDB24 DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY TO METFORMIN (MET)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00671-1&doi=10.1016/j.jval.2011.02.532
First page :
A95
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1096